297 related articles for article (PubMed ID: 29076951)
1. Cisplatin, dacarbazine and vinblastine as first line chemotherapy for liver metastatic uveal melanoma in the era of immunotherapy: a single institution phase II study.
Schinzari G; Rossi E; Cassano A; Dadduzio V; Quirino M; Pagliara M; Blasi MA; Barone C
Melanoma Res; 2017 Dec; 27(6):591-595. PubMed ID: 29076951
[TBL] [Abstract][Full Text] [Related]
2. Study design and rationale for a randomised, placebo-controlled, double-blind study to assess the efficacy of selumetinib (AZD6244; ARRY-142886) in combination with dacarbazine in patients with metastatic uveal melanoma (SUMIT).
Carvajal RD; Schwartz GK; Mann H; Smith I; Nathan PD
BMC Cancer; 2015 Jun; 15():467. PubMed ID: 26059332
[TBL] [Abstract][Full Text] [Related]
3. Liver metastases from uveal melanoma: clinical experience of hepatic arterial infusion of cisplatin, vinblastine and dacarbazine.
Melichar B; Voboril Z; Lojík M; Krajina A
Hepatogastroenterology; 2009; 56(93):1157-62. PubMed ID: 19760961
[TBL] [Abstract][Full Text] [Related]
4. Systemic therapy for unresectable metastatic melanoma: impact of biochemotherapy on long-term survival.
Bedikian AY; Johnson MM; Warneke CL; McIntyre S; Papadopoulos N; Hwu WJ; Kim K; Hwu P
J Immunotoxicol; 2008 Apr; 5(2):201-7. PubMed ID: 18569391
[TBL] [Abstract][Full Text] [Related]
5. Phase II Trial of Bevacizumab in Combination With Temozolomide as First-Line Treatment in Patients With Metastatic Uveal Melanoma.
Piperno-Neumann S; Diallo A; Etienne-Grimaldi MC; Bidard FC; Rodrigues M; Plancher C; Mariani P; Cassoux N; Decaudin D; Asselain B; Servois V
Oncologist; 2016 Mar; 21(3):281-2. PubMed ID: 26911405
[TBL] [Abstract][Full Text] [Related]
6. Chemoimmunotherapy with bleomycin, vincristine, lomustine, dacarbazine (BOLD), and human leukocyte interferon for metastatic uveal melanoma.
Pyrhönen S; Hahka-Kemppinen M; Muhonen T; Nikkanen V; Eskelin S; Summanen P; Tarkkanen A; Kivelä T
Cancer; 2002 Dec; 95(11):2366-72. PubMed ID: 12436444
[TBL] [Abstract][Full Text] [Related]
7. A prospective single arm phase II study of dacarbazine and treosulfan as first-line therapy in metastatic uveal melanoma.
O'Neill PA; Butt M; Eswar CV; Gillis P; Marshall E
Melanoma Res; 2006 Jun; 16(3):245-8. PubMed ID: 16718271
[TBL] [Abstract][Full Text] [Related]
8. Selumetinib in Combination With Dacarbazine in Patients With Metastatic Uveal Melanoma: A Phase III, Multicenter, Randomized Trial (SUMIT).
Carvajal RD; Piperno-Neumann S; Kapiteijn E; Chapman PB; Frank S; Joshua AM; Piulats JM; Wolter P; Cocquyt V; Chmielowski B; Evans TRJ; Gastaud L; Linette G; Berking C; Schachter J; Rodrigues MJ; Shoushtari AN; Clemett D; Ghiorghiu D; Mariani G; Spratt S; Lovick S; Barker P; Kilgour E; Lai Z; Schwartz GK; Nathan P
J Clin Oncol; 2018 Apr; 36(12):1232-1239. PubMed ID: 29528792
[TBL] [Abstract][Full Text] [Related]
9. Transarterial chemoembolization of liver metastases from uveal melanoma after failure of systemic therapy: toxicity and outcome.
Schuster R; Lindner M; Wacker F; Krössin M; Bechrakis N; Foerster MH; Thiel E; Keilholz U; Schmittel A
Melanoma Res; 2010 Jun; 20(3):191-6. PubMed ID: 20335820
[TBL] [Abstract][Full Text] [Related]
10. Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): a trial coordinated by the Eastern Cooperative Oncology Group.
Atkins MB; Hsu J; Lee S; Cohen GI; Flaherty LE; Sosman JA; Sondak VK; Kirkwood JM;
J Clin Oncol; 2008 Dec; 26(35):5748-54. PubMed ID: 19001327
[TBL] [Abstract][Full Text] [Related]
11. Predictive biomarkers to chemotherapy in patients with advanced melanoma receiving the combination of cisplatin--vinblastine--temozolomide (PVT) as first-line treatment: a study of the Hellenic Cooperative Oncology Group (HECOG).
Linardou H; Pentheroudakis G; Varthalitis I; Gogas H; Pectasides D; Makatsoris T; Fountzilas G; Bafaloukos D;
Anticancer Res; 2015 Feb; 35(2):1105-13. PubMed ID: 25667500
[TBL] [Abstract][Full Text] [Related]
12. A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin 2, and interferon alpha-2B in patients with metastatic melanoma.
McDermott DF; Mier JW; Lawrence DP; van den Brink MR; Clancy MA; Rubin KM; Atkins MB
Clin Cancer Res; 2000 Jun; 6(6):2201-8. PubMed ID: 10873069
[TBL] [Abstract][Full Text] [Related]
13. Phase II DeCOG-study of ipilimumab in pretreated and treatment-naïve patients with metastatic uveal melanoma.
Zimmer L; Vaubel J; Mohr P; Hauschild A; Utikal J; Simon J; Garbe C; Herbst R; Enk A; Kämpgen E; Livingstone E; Bluhm L; Rompel R; Griewank KG; Fluck M; Schilling B; Schadendorf D
PLoS One; 2015; 10(3):e0118564. PubMed ID: 25761109
[TBL] [Abstract][Full Text] [Related]
14. Effect of selumetinib vs chemotherapy on progression-free survival in uveal melanoma: a randomized clinical trial.
Carvajal RD; Sosman JA; Quevedo JF; Milhem MM; Joshua AM; Kudchadkar RR; Linette GP; Gajewski TF; Lutzky J; Lawson DH; Lao CD; Flynn PJ; Albertini MR; Sato T; Lewis K; Doyle A; Ancell K; Panageas KS; Bluth M; Hedvat C; Erinjeri J; Ambrosini G; Marr B; Abramson DH; Dickson MA; Wolchok JD; Chapman PB; Schwartz GK
JAMA; 2014 Jun; 311(23):2397-405. PubMed ID: 24938562
[TBL] [Abstract][Full Text] [Related]
15. Pembrolizumab as first-line treatment for metastatic uveal melanoma.
Rossi E; Pagliara MM; Orteschi D; Dosa T; Sammarco MG; Caputo CG; Petrone G; Rindi G; Zollino M; Blasi MA; Cassano A; Bria E; Tortora G; Schinzari G
Cancer Immunol Immunother; 2019 Jul; 68(7):1179-1185. PubMed ID: 31175402
[TBL] [Abstract][Full Text] [Related]
16. A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, temozolomide, interleukin 2, and IFN-alpha 2B in patients with metastatic melanoma.
Atkins MB; Gollob JA; Sosman JA; McDermott DF; Tutin L; Sorokin P; Parker RA; Mier JW
Clin Cancer Res; 2002 Oct; 8(10):3075-81. PubMed ID: 12374674
[TBL] [Abstract][Full Text] [Related]
17. Does complete response to systemic therapy in patients with stage IV melanoma translate into long-term survival?
Bedikian AY; Johnson MM; Warneke CL; Papadopoulos NE; Kim KB; Hwu WJ; McIntyre S; Rohlfs M; Homsi J; Hwu P
Melanoma Res; 2011 Feb; 21(1):84-90. PubMed ID: 21102360
[TBL] [Abstract][Full Text] [Related]
18. Development of a biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, dacarbazine, interferon alfa, and interleukin-2 for patients with metastatic melanoma.
Legha SS; Ring S; Eton O; Bedikian A; Buzaid AC; Plager C; Papadopoulos N
J Clin Oncol; 1998 May; 16(5):1752-9. PubMed ID: 9586888
[TBL] [Abstract][Full Text] [Related]
19. A prospective trial of adjuvant therapy for high-risk uveal melanoma: assessing 5-year survival outcomes.
Binkley E; Triozzi PL; Rybicki L; Achberger S; Aldrich W; Singh A
Br J Ophthalmol; 2020 Apr; 104(4):524-528. PubMed ID: 31371315
[TBL] [Abstract][Full Text] [Related]
20. Phase II trial of sorafenib in combination with carboplatin and paclitaxel in patients with metastatic uveal melanoma: SWOG S0512.
Bhatia S; Moon J; Margolin KA; Weber JS; Lao CD; Othus M; Aparicio AM; Ribas A; Sondak VK
PLoS One; 2012; 7(11):e48787. PubMed ID: 23226204
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]